Veeda Clinical Research Unlisted Shares
Veeda Clinical Research buys European CRO Heads for an undisclosed sum
Business Standard
2 min read
Veeda Clinical Research buys European CRO Heads for an undisclosed sum.
Expert Analysis:
Veeda Acquires Heads: Veeda Clinical Research acquires Heads, a European CRO specializing in oncology trials, to strengthen its global market position.
Global Expansion and Expertise: Veeda expands into major regions, gaining expertise in late-stage oncology trials, while Heads gains access to Indian and Southeast Asian markets.
Heads' Global Presence and Expertise: Founded in 2010, Heads operates in 25 locations across Europe, North America, and Asia Pacific, adding oncology expertise to Veeda’s portfolio for comprehensive drug development services.
Expanded Therapeutic Opportunities: Heads gain access to India’s diverse patient population for trials in oncology, diabetes, hypertension, and more, enhancing Veeda’s CRO services globally.
CEO Statement on Acquisition: Mahesh Bhalgat, Group CEO of Veeda, States that the acquisition's role is enabling large-scale, multi-geography clinical trials and fostering innovative treatments.
Binoy Gardi on Integration: Binoy Gardi, Executive Vice Chairperson of Veeda, states that the opportunity to expand markets, leverage complementary capabilities, and add value to clients during integration.
Veeda’s acquisition of Heads expands global presence, enhances oncology capabilities, and opens access to diverse patient populations in India and Southeast Asia.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved